Bleeding incidence and risk factors among cancer patients treated with anticoagulation
Author:
Affiliation:
1. Department of Hematology and Medical OncologyTaussig Cancer Institute, Cleveland Clinic Foundation Cleveland Ohio
2. Quantitative Health SciencesLerner Research Institute, Cleveland Clinic Foundation Cleveland Ohio
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25494
Reference14 articles.
1. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis;Prandoni P;Blood,2002
2. Comparison of low‐molecular‐weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study;Meyer G;Arch Intern Med,2002
3. Long‐term low‐molecular‐weight heparin versus usual care in proximal‐vein thrombosis patients with cancer;Hull RD;Am J Med,2006
4. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis;Hutten BA;J Clin Oncol,2000
5. Edoxaban for the treatment of cancer‐associated venous thromboembolism;Raskob GE;N Engl J Med,2018
Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Management of cancer-associated thromboembolism in vulnerable population;Archives of Cardiovascular Diseases;2024-01
2. Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-01
3. Personalized medicine for disorders of hemostasis and thrombosis;Diagnostic Molecular Pathology;2024
4. Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis;Cancers;2023-12-18
5. Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer;Cancers;2023-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3